NO20083248L - Imidazoler som GABA-B reseptormodulatorer - Google Patents

Imidazoler som GABA-B reseptormodulatorer

Info

Publication number
NO20083248L
NO20083248L NO20083248A NO20083248A NO20083248L NO 20083248 L NO20083248 L NO 20083248L NO 20083248 A NO20083248 A NO 20083248A NO 20083248 A NO20083248 A NO 20083248A NO 20083248 L NO20083248 L NO 20083248L
Authority
NO
Norway
Prior art keywords
compounds
alkyl
treatment
gaba
imidazoles
Prior art date
Application number
NO20083248A
Other languages
English (en)
Inventor
Udo Bauer
Linda Gustafsson
Maria Saxin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20083248L publication Critical patent/NO20083248L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår nye forbindelser som har en positiv allosterisk GABAB reseptor (GBR) modulerende effekt, fremgangsmåter for fremstilling av nevnte forbindelser og deres anvendelse, eventuelt i kombinasjon med en GABAB agonist, for inhibering av forbigående lavere spiserørlukkemuskelrelaksasjoner, for behandling av gastrospiserørreflukssykdom, så vel som for behandling av funksjonelle gastrointestinale forstyrrelser og irritabel tarmsyndrom (IBS). Forbindelsene er representert ved den generelle formelen (I) hvori R1, R2, R3 og R4 er som definert i beskrivelsen. For eksempel kan enhver alkyl eller arylalky, R2 være alkyl, R3 kan være alkoksy og R4 kan være en substituent som inneholder en arylgruppe.
NO20083248A 2005-12-23 2008-07-22 Imidazoler som GABA-B reseptormodulatorer NO20083248L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502905 2005-12-23
PCT/SE2006/001463 WO2007073299A1 (en) 2005-12-23 2006-12-21 Imidazoles as gaba-b receptor modulators

Publications (1)

Publication Number Publication Date
NO20083248L true NO20083248L (no) 2008-07-23

Family

ID=38188930

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083248A NO20083248L (no) 2005-12-23 2008-07-22 Imidazoler som GABA-B reseptormodulatorer

Country Status (12)

Country Link
US (1) US20080312305A1 (no)
EP (1) EP1968946A4 (no)
JP (1) JP2009521429A (no)
KR (1) KR20080090448A (no)
CN (1) CN101341131A (no)
AU (1) AU2006327316A1 (no)
BR (1) BRPI0620373A2 (no)
CA (1) CA2632020A1 (no)
IL (1) IL191767A0 (no)
NO (1) NO20083248L (no)
WO (1) WO2007073299A1 (no)
ZA (1) ZA200805160B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401653D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
US20090062365A1 (en) * 2005-12-23 2009-03-05 Udo Bauer Pyrazoles for the Treatment of GERD and IBS
WO2007073300A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
US20080312291A1 (en) * 2005-12-23 2008-12-18 Udo Bauer Heterocyclic Gaba-b Modulators
US7745474B2 (en) * 2005-12-23 2010-06-29 Astrazeneca Ab Imidazole derivatives for the treatment of gastrointestinal disorders
NZ601967A (en) 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US10653672B2 (en) 2014-02-07 2020-05-19 National University Corporation Tokyo Medical And Dental University Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
EP3285760A4 (en) 2015-04-24 2018-09-26 Omeros Corporation Pde10 inhibitors and related compositions and methods
AU2016284399A1 (en) * 2015-06-22 2018-02-01 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic heterocyclic amide derivative
AU2016284398C1 (en) 2015-06-22 2021-01-07 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態
US10898469B2 (en) 2016-02-26 2021-01-26 Sumitomo Dainippon Pharma Co., Ltd. Imidazolylamide derivative

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3876655A (en) * 1971-08-18 1975-04-08 Beecham Group Ltd Anti-inflammatory acyl imidazoles
US4659720A (en) * 1982-12-20 1987-04-21 Merck & Co., Inc. 5-amino or substituted amino imidazoles useful to treat coccidiosis
FR2663934B1 (fr) * 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
US5214063A (en) * 1990-06-27 1993-05-25 Adir Et Compagnie 4-aminobutyric acid compounds, compositions and methods of use for treating disorders related to a dysfunction of GABAB receptors
DE4213750A1 (de) * 1992-04-25 1993-10-28 Basf Ag Verfahren zur Herstellung von 3-(Hydroxyphenyl)-propionaldehyden und gegebenenfalls der Herstellung von 3-(hydroxyphenyl)-propanolen
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
AU5859598A (en) * 1996-12-24 1998-07-17 Novartis Ag (thio)morpholine-substituted carboxylic and phosphinic acids
US20040259883A1 (en) * 2001-09-14 2004-12-23 Hiroshi Sakashita Thiazolidine derivative and medicinal use thereof
SE0401653D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
US20090062365A1 (en) * 2005-12-23 2009-03-05 Udo Bauer Pyrazoles for the Treatment of GERD and IBS
US7745474B2 (en) * 2005-12-23 2010-06-29 Astrazeneca Ab Imidazole derivatives for the treatment of gastrointestinal disorders
WO2007073300A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
US20080312291A1 (en) * 2005-12-23 2008-12-18 Udo Bauer Heterocyclic Gaba-b Modulators
BRPI0810019A2 (pt) * 2007-04-18 2014-10-14 Astrazeneca Ab Composto, composição farmacêutica, e, uso de um composto
US20080262064A1 (en) * 2007-04-18 2008-10-23 Astrazeneca Ab Novel Compounds For The Treatment Of GI Disorders 682

Also Published As

Publication number Publication date
ZA200805160B (en) 2009-10-28
EP1968946A1 (en) 2008-09-17
JP2009521429A (ja) 2009-06-04
US20080312305A1 (en) 2008-12-18
AU2006327316A1 (en) 2007-06-28
CN101341131A (zh) 2009-01-07
WO2007073299A1 (en) 2007-06-28
CA2632020A1 (en) 2007-06-28
EP1968946A4 (en) 2010-05-05
IL191767A0 (en) 2008-12-29
KR20080090448A (ko) 2008-10-08
BRPI0620373A2 (pt) 2011-11-08

Similar Documents

Publication Publication Date Title
NO20083248L (no) Imidazoler som GABA-B reseptormodulatorer
NO20083247L (no) GABA-B reseptormodulatorer
NO20083244L (no) Heterosykliske GABA-B modulatorer
NO20083249L (no) Imidazolderivater for behandling av gastrointestinale forstyrrelser
NO20083243L (no) Pyrazoler for behandling av GERD og IBS
EA200870489A1 (ru) Пиперидинилзамещённые пирролидиноны в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы 1
SMT201300085B (it) Composti di pirrolo
DK2021337T3 (da) Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1
PH12014501033A1 (en) Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
NO20085140L (no) Nye indazolderivater som har spiro ringstruktur i sidekjede
EA201070039A1 (ru) Спироциклы в качестве ингибиторов 11-бета гидроксилстероиддегидрогеназы типа 1
DK2021336T3 (da) 11-beta-hydroxysteroid-dehydrogenase-1-inhibitorer
PE20091425A1 (es) Derivados de aminotiazol
EA200901098A1 (ru) Производные тиазола в качестве модуляторов сопряженных с g-белком рецепторов
EA200870476A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
EA200971044A1 (ru) Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
NO20084262L (no) Nye 1,2,3,4-tetrahydrokinoksalinderivater som har glukokortikoidreseptorbindende aktivitet
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
AR072242A1 (es) Derivados de imidazopiridina, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neuromusculares.
BRPI0811200A8 (pt) Tetra-hidrobenzapinas arilóxi- e heteroarilóxi-substituídas e uso das mesmas para bloquear percepção de norepinefrina, dopamina, e serotonina
TR201906117T4 (tr) Nitrokatesollere yönelik uygulama rejimi.
WO2010003084A3 (en) Phosphodiesterase 4 inhibitors
BR112012005902A2 (pt) formulação de catalisador de quelato de ti, uso da formulação de catalisador de quelato de ti ou de um composto, composição, processo para a polimeração de compostos, catalisador de quelato de ti, uso da composição polimerizável, e, substrato revestido

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application